Close Menu

NEW YORK – Lucid Diagnostics, a PAVmed subsidiary, said Thursday that it has received breakthrough device designation from the US Food and Drug Administration for a test to detect esophageal dysplasia and potential cancer risk.

Called the EsoGuard Esophageal DNA Test, the assay is meant to be performed on esophageal samples collected using the firm's EsoCheck Cell Collection Device in a well-defined group of patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease, or GERD.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.